- United Kingdom
- /
- Life Sciences
- /
- AIM:IXI
IXICO First Half 2025 Earnings: UK£0.011 loss per share (vs UK£0.029 loss in 1H 2024)
IXICO (LON:IXI) First Half 2025 Results
Key Financial Results
- Revenue: UK£3.21m (up 26% from 1H 2024).
- Net loss: UK£958.0k (loss narrowed by 32% from 1H 2024).
- UK£0.011 loss per share (improved from UK£0.029 loss in 1H 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IXICO shares are up 28% from a week ago.
Risk Analysis
We should say that we've discovered 4 warning signs for IXICO (2 don't sit too well with us!) that you should be aware of before investing here.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About AIM:IXI
IXICO
Provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, the Netherlands, Ireland, rest of Europe, and the United States.
Flawless balance sheet slight.
Market Insights
Community Narratives

